NCT05707819 is a clinical trial of Sintilimab (PD-1 Antibody) in Nasopharyngeal Carcinoma, sponsored by Cancer Hospital of Guangxi Medical University.

Who is sponsoring NCT05707819?

NCT05707819 is sponsored by Cancer Hospital of Guangxi Medical University.

What drugs are being tested in NCT05707819?

Interventions in NCT05707819: Sintilimab (PD-1 Antibody).

What condition does NCT05707819 study?

NCT05707819 studies Nasopharyngeal Carcinoma, Sintilimab.

Is NCT05707819 still recruiting?

NCT05707819 is currently recruiting now. Last updated 1 February 2023.

Last reviewed 2023-02-01 · How we verify

NCT05707819

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Recruiting now Last updated 1 February 2023

What this trial tests

trial testing Sintilimab (PD-1 Antibody) in Nasopharyngeal Carcinoma in 43 participants. Currently enrolling.

Timeline

30 July 2022

Primary endpoint
31 December 2023

31 December 2028

Quick facts

Lead sponsor	Cancer Hospital of Guangxi Medical University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	43
Start date	30 July 2022
Primary completion	31 December 2023
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

Sintilimab (PD-1 Antibody) — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →
Sintilimab — all drugs for Sintilimab →

Sponsor

Cancer Hospital of Guangxi Medical University

Who can join

Adults 18 to 70, any sex, with Nasopharyngeal Carcinoma or Sintilimab. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The program aims to enroll patients with stage high risk (AJCC 8th, T3-4N2-3M0) . Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
Zhang YN, Chen YP, OuYang PY, Lu TX, et al · · 2025 · cited 3× · PMID 39896749 · DOI 10.1177/17588359251316094
Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma.
Shang K, He Q, Xu X, Luo X, et al · · 2025 · cited 1× · PMID 39802955 · DOI 10.2147/tcrm.s489899

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Cancer Hospital of Guangxi Medical University trials

Trials by the same sponsor.

NCT05131698 — Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenv · EARLY_PHASE1 · unknown
NCT03914352 — A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05707819 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Hospital of Guangxi Medical University
Last refreshed: 1 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05707819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing